PTPRD and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions: <i>PTPRD</i> mutation might be a favorable indicator for Xp11.2 tRCC patients managed by PN and followed by the adjuvant therapy of immune checkpoint inhibitor and tyrosine kinase inhibitor.